DiaMedica Therapeutics Inc.
DMAC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $6 | $6 | $6 | $6 |
| G&A Expenses | $0 | $2 | $2 | $0 |
| SG&A Expenses | $3 | $2 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $9 | $8 | $8 | $8 |
| Operating Income | -$9 | -$8 | -$8 | -$8 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | $1 |
| Pre-Tax Income | -$9 | -$8 | -$8 | -$8 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$9 | -$8 | -$8 | -$8 |
| % Margin | – | – | – | – |
| EPS | -0.17 | -0.18 | -0.18 | -0.18 |
| % Growth | 5.6% | 0% | 0% | – |
| EPS Diluted | -0.17 | -0.18 | -0.18 | -0.18 |
| Weighted Avg Shares Out | 50 | 43 | 43 | 43 |
| Weighted Avg Shares Out Dil | 50 | 43 | 43 | 43 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$9 | -$8 | -$8 | -$8 |
| % Margin | – | – | – | – |